Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 618

Results For "RI"

10423 News Found

PharmaLytica 2024 to draw 200+ exhibitors
News | April 19, 2024

PharmaLytica 2024 to draw 200+ exhibitors

10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad


Biocon inks agreement for Ozempic commercialization in Brazil with Biomm
News | April 19, 2024

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market


Shilpa Medicare launches Pemetrexed injection
News | April 19, 2024

Shilpa Medicare launches Pemetrexed injection

Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents


Fresenius Kabi USA flies complaint against NATCO Pharma
News | April 19, 2024

Fresenius Kabi USA flies complaint against NATCO Pharma

Natco Pharma intends to defend the matter accordingly


AIC-CCMB signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India
News | April 19, 2024

AIC-CCMB signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India

Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform


Jubilant Pharmova’s Roorkee unit gets VAI status
Drug Approval | April 18, 2024

Jubilant Pharmova’s Roorkee unit gets VAI status

FDA has concluded that this inspection is 'closed'


GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Drug Approval | April 17, 2024

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

Submission based on results from pivotal phase III trial showing all primary endpoints met


AbbVie announces late-breaking data at AAN supporting efficacy of Atogepant for preventive treatment of migraine
Clinical Trials | April 17, 2024

AbbVie announces late-breaking data at AAN supporting efficacy of Atogepant for preventive treatment of migraine

Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine


Alvotech and Teva get US FDA approval of Selarsdi
Drug Approval | April 17, 2024

Alvotech and Teva get US FDA approval of Selarsdi

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva